GSK’s Nucala (Mepolizumab) Receives Japanese Approval for Treating Chronic Rhinosinusitis with Nasal Polyps
Shots:
- The MHLW has approved Nucala (IL-5 targeting mAb) to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in adults inadequately controlled with standard treatment
- Approval was supported by the P-III (MERIT) study evaluating the safety & effectiveness of Nucala for 52wks. among Japanese, Chinese & Russian patients plus the results from P-III (SYNAPSE) trial of Nucala vs PBO involving over 400 patients worldwide
- MERIT study showed improved nasal obstruction VAS score & patient quality of life (as per 22-item Sino-Nasal Outcome Test). Safety and tolerability were consistent, with a similar proportion of AEs in both the groups (7 had TRAEs). No SAEs were reported
Ref: GSK | Image: GSK
Related News:- GSK’s Nucala (mepolizumab) Receives the China’s NMPA Approval for Severe Eosinophilic Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
